Compare ENTX & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | FSP |
|---|---|---|
| Founded | 2010 | 1981 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 72.4M |
| IPO Year | 2015 | 2001 |
| Metric | ENTX | FSP |
|---|---|---|
| Price | $1.25 | $0.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 138.7K | ★ 318.8K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 6.34% |
| EPS Growth | N/A | ★ 15.69 |
| EPS | ★ 0.07 | N/A |
| Revenue | $42,000.00 | ★ $107,162,000.00 |
| Revenue This Year | N/A | $17.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.51 |
| 52 Week High | $3.22 | $1.88 |
| Indicator | ENTX | FSP |
|---|---|---|
| Relative Strength Index (RSI) | 51.94 | 33.84 |
| Support Level | $1.17 | N/A |
| Resistance Level | $1.37 | $0.70 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 61.67 | 7.54 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.